Summary
CI-940, PD 114,721, and PD 118,607 are structurally novel antibiotics, which were isolated from fermentation beers of a previously unknown actinomycete. They are highly lipophilic acids characterized by unsaturated lactone and branched, polyunsaturated aliphatic sidechain moieties. All three agents demonstrated significant cytotoxic activity in vitro against a number of human and mouse tumour lines which encompassed a wide range of tissue types. CI-940 retained full activity in vitro against lines of P388 leukemia that are resistant to Adriamycin, amsacrine, and mitoxantrone. Activity was confirmed for both CI-940 and PD 114,721 against a number of murine experimental tumor systems in vivo, which included the P388 and L1210 leukemias and also B16 melanoma, Ridgway osteogenic and M5076 sarcomas, and mammary adenocarcinoma 16/C. PD 118,607 was also highly active against B16 melanoma. All three agents demonstrated anticancer activity at very low dosages compared with current clinically useful anticancer agents. No significant activity was seen against the MX-1 human mammary xenograft or pancreas 02 tumor models. The primary target for host toxicity of CI-940 and PD 114,721 appeared to be gastrointestinal in nature. Neither CI-940 nor PD 114,721 caused delayed lethality when given either IP or IV. In schedule studies, the toxicities of both CI-940 and PD 114,721 were moderately dependent on the regimen used, with total maximum tolerated dosages for intermittent (q4dx2), daily (qdx5), and divided daily (q4hx3, qdx5) dosing schedules of 1, 0.25, and 0.12 mg/kg, respectively.
CI-940 is being developed for clinical trial on the basis of its potent activity against seven different tumor models, its novel structure, and its apparently novel mechanism of action.
Similar content being viewed by others
References
Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold, DP Jr, Schabel FM Jr (1982) Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 42: 1707
Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44:717
Finlay GJ, Baguley BC, Wilson WR (1983) A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 139:272
Fry DW, Boritzki TJ, Jackson RC (1984a) Studies on the biochemical mechanism of the novel antitumor agent, CI-920. cancer Chemother Pharmacol 13:171
Fry DW, Besserer JA, Boritzki TJ (1984b) Transport of the antitumor antibiotic CI-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res 44:3366
Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems, 3rd edn. Cancer Chemother Rep [3] 3 (2):1
Hamamoto T, Gunji S, Tsuji H, Beppu T (1983a) Leptomycins A and B, new antifungal antibiotics: I. Taxonomy of the producing strain and their fermentation, purification and characterization. J Antibiot (Tokyo) 36:639
Hamamoto T, Seto H, Beppu T (1983b) Leptomycins A and B, new antifungal antibiotics: II. Structure elucidation. J Antibiot (Tokyo) 36:646
Hokanson GC, French JC (1985) Novel antitumor agents CI-920, PD 113270, and PD 113271. 3. Structure determination. J Org Chem 50:462
Jackson RC, Fry DW, Boritzki TJ, Roberts BJ, Hook KE, Leopold WR (1985) The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity. Adv Enzyme Regul 23:193
Komiyama K, Okada K, Hirokawa Y, Masuda K, Tomisaka S, Umezawa I (1985) Antitumor activity of a new antibiotic, Kazusamycin. J Antibiot (Tokyo) 38:224
Leopold WR, Shillis JL, Mertus AE, Nelson JM, Roberts BJ, Jackson RC (1984) Anticancer activity of the structurally novel antibiotic CI-920 and its analogues. Cancer Res 44:1928
Schabel FM Jr, Griswold DP Jr, Laster WR Jr, Corbett TH, Lloyd HH (1977) Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther 1:411
Schaumberg JP, Hokanson GC, French JC (1984) The structures of the antitumor antibiotics, PD 114,720 and PD 114,721. J Chem Soc [Chem Commun] 1450
Stampwala SS, Bunge RH, Hurley TR, Willmer NE, Brankiewicz AJ, Steinman CE, Smitka TA, French JC (1983) Novel antitumor agents CI-920, PD 113,270, and PD 113,271: II. Isolation and characterization. J Antibiot (Tokyo) 36:1601
Tunac JB, Graham BJ, Dobson WE (1983) Novel antitumor agents CI-920, PD 113,270, and PD 113,271: I. Taxonomy, fermentation, and biological properties. J Antibiot (Tokyo) 36:1595
Tunac JB, Graham BD, Dobson WE, Lenzini MD (1985) Novel antitumor antibiotics, CI-940 (PD 114,720) and PD 114,721: Taxonomy, fermentation, and biological activity. J Antibiot (Tokyo) 38:460
Umezawa I, Komiyama K, Oka H, Okada K, Tomisaka S, Miyano T, Takano S (1984) A new antitumor antibiotic, Kazusamycin. J Antibiot (Tokyo) 37:706
Author information
Authors and Affiliations
Additional information
This work was supported in part by USPHS Contract NO1-CM-37614.
Rights and permissions
About this article
Cite this article
Roberts, B.J., Hamelehle, K.L., Sebolt, J.S. et al. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother. Pharmacol. 16, 95–101 (1986). https://doi.org/10.1007/BF00256156
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00256156